Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

29.4%

5 terminated/withdrawn out of 17 trials

Success Rate

68.8%

-17.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 11 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

11(64.7%)

Phase 1

4(23.5%)

N/A

2(11.8%)

17Total

Phase 2(11)

Phase 1(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT01965041Not ApplicableWithdrawn

Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy

Role: lead

NCT01974622Not ApplicableUnknown

ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study

Role: lead

NCT00211393Phase 2Completed

A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

Role: lead

NCT00211458Phase 2Completed

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

Role: lead

NCT00489840Phase 1Completed

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

Role: lead

NCT00211432Phase 2Completed

Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Role: lead

NCT00470977Phase 1Completed

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

Role: lead

NCT00211315Phase 2Completed

Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

Role: lead

NCT00211419Phase 1Completed

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Role: lead

NCT00211354Phase 2Withdrawn

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

Role: lead

NCT00211328Phase 2Completed

Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).

Role: lead

NCT00211445Phase 2Completed

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

Role: lead

NCT00140803Phase 2Completed

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Role: lead

NCT00211367Phase 2Terminated

Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Role: lead

NCT00211406Phase 1Terminated

Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Role: lead

NCT00211484Phase 2Completed

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

Role: lead

NCT00211471Phase 2Terminated

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

Role: lead

All 17 trials loaded